Novo Nordisk's Wegovy Shows Strong Weight Loss and Fat Reduction in New Clinical Data

Novo Nordisk presented new analyses from its STEP UP trial at the European Congress on Obesity in May 2026, showing that a higher 7.2 mg dose of Wegovy (semaglutide) achieved a 21% average body weight loss at 72 weeks, compared to 17.5% with the approved 2.4 mg dose . The data adds to a growing body of evidence supporting dose escalation for patients who do not achieve sufficient weight loss on standard doses.

Critically, the trial revealed that 84% of weight loss on Wegovy came from fat mass reduction while preserving muscle function — a finding that differentiates the drug from older weight-loss therapies that eroded lean mass. Among early responders achieving at least 15% weight loss by week 24, the 7.2 mg dose produced a mean 27.7% weight reduction by week 72, with roughly one-third of this high-response group losing at least 25% of body weight .

The results reinforce NVO's competitive position in the GLP-1 market, where it faces intensifying pressure from Eli Lilly's tirzepatide (Zepbound). A higher-dose option that delivers near-30% weight loss for early responders could open new labeling and pricing opportunities, though the 7.2 mg formulation has not yet received regulatory approval and will require additional safety and efficacy review before commercialization.

Related Stocks

• NVO